Maksoud Ziad, Schmidt Manuel Alexander, Huang Yixing, Rutzner Sandra, Mansoorian Sina, Weissmann Thomas, Bert Christoph, Distel Luitpold, Semrau Sabine, Lettmaier Sebastian, Eyüpoglu Ilker, Fietkau Rainer, Putz Florian
Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Universitaetsstraße 27, 91054 Erlangen, Germany.
Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.
Cancers (Basel). 2022 Mar 17;14(6):1547. doi: 10.3390/cancers14061547.
To investigate the occurrence of pseudoprogression/transient enlargement in meningiomas after stereotactic radiotherapy (RT) and to evaluate recently proposed volumetric RANO meningioma criteria for response assessment in the context of RT. Sixty-nine meningiomas (benign: 90%, atypical: 10%) received stereotactic RT from January 2005-May 2018. A total of 468 MRI studies were segmented longitudinally during a median follow-up of 42.3 months. Best response and local control were evaluated according to recently proposed volumetric RANO criteria. Transient enlargement was defined as volumetric increase ≥20% followed by a subsequent regression ≥20%. The mean best volumetric response was -23% change from baseline (range, -86% to +19%). According to RANO, the best volumetric response was SD in 81% (56/69), MR in 13% (9/69) and PR in 6% (4/69). Transient enlargement occurred in only 6% (4/69) post RT but would have represented 60% (3/5) of cases with progressive disease if not accounted for. Transient enlargement was characterized by a mean maximum volumetric increase of +181% (range, +24% to +389 %) with all cases occurring in the first year post-RT (range, 4.1-10.3 months). Transient enlargement was significantly more frequent with SRS or hypofractionation than with conventional fractionation (25% vs. 2%, = 0.015). Five-year volumetric control was 97.8% if transient enlargement was recognized but 92.9% if not accounted for. Transient enlargement/pseudoprogression in the first year following SRS and hypofractionated RT represents an important differential diagnosis, especially because of the high volumetric control achieved with stereotactic RT. Meningioma enlargement during subsequent post-RT follow-up and after conventional fractionation should raise suspicion for tumor progression.
研究立体定向放射治疗(RT)后脑膜瘤中假性进展/短暂性增大的发生情况,并在RT背景下评估最近提出的用于反应评估的RANO脑膜瘤体积标准。2005年1月至2018年5月期间,69例脑膜瘤(良性:90%,非典型性:10%)接受了立体定向RT。在中位随访42.3个月期间,共对468份MRI研究进行了纵向分割。根据最近提出的体积RANO标准评估最佳反应和局部控制情况。短暂性增大定义为体积增加≥20%,随后体积缩小≥20%。平均最佳体积反应为相对于基线变化-23%(范围,-86%至+19%)。根据RANO标准,最佳体积反应为疾病稳定(SD)的占81%(56/69),部分缓解(MR)的占13%(9/69),完全缓解(PR)的占6%(4/69)。RT后仅6%(4/69)出现短暂性增大,但如果不考虑这一情况,其在疾病进展病例中所占比例将达60%(3/5)。短暂性增大的特征为平均最大体积增加+181%(范围,+24%至+389%),所有病例均发生在RT后第一年(范围,4.1 - 10.3个月)。与传统分割放疗相比,立体定向放射外科(SRS)或低分割放疗后短暂性增大的发生率显著更高(25%对2%,P = 0.015)。如果认识到短暂性增大,五年体积控制率为97.8%,但如果不考虑这一情况,则为92.9%。SRS和低分割放疗后第一年的短暂性增大/假性进展是一个重要的鉴别诊断,特别是考虑到立体定向RT能实现较高的体积控制率。RT后续随访期间以及传统分割放疗后出现的脑膜瘤增大应怀疑肿瘤进展。